Literature DB >> 27074052

Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.

Hesham M Hassan1, Michelle L Varney1, Nagendra K Chaturvedi2, Shantaram S Joshi2, Dennis D Weisenburger3, Rakesh K Singh1, Bhavana J Dave1,4.   

Abstract

Mantle cell lymphoma (MCL) is characterized by a clinically aggressive course with frequent relapse and poor survival. The p53 pathway is frequently dysregulated and p53 status predicts clinical outcome. In this report, we investigated whether modulation of p73 isoforms by diclofenac inhibits cell growth, induces apoptosis and/or cell cycle arrest in MCL relative to p53 status. Wild-type p53 [Granta-519 and JVM-2], mutant p53 [Jeko-1 and Mino-1] expressing cells, therapy resistant cell lines, and primary human cells isolated from MCL patients were used. Overexpression of pro-apoptotic TAp73 enhanced MCL cell apoptosis. Diclofenac induced a concentration- and duration-dependent increase in TAp73, cell cycle arrest, cell death, and inhibited MCL cell growth independent of p53 status. Diclofenac treatment was associated with increased activity of caspases 3, 7, and 8 and induction of p53 transcriptional target genes. These studies demonstrate the potential for diclofenac as novel therapeutic agent in MCL independent of p53 status.

Entities:  

Keywords:  Apoptosis; cell cycle; diclofenac; mantle cell lymphoma; p73 isoforms

Mesh:

Substances:

Year:  2016        PMID: 27074052      PMCID: PMC5967247          DOI: 10.3109/10428194.2016.1165814

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  42 in total

1.  Rearrangements of chromosome band 1p36 in non-Hodgkin's lymphoma.

Authors:  B J Dave; M M Hess; D L Pickering; D H Zaleski; A L Pfeifer; D D Weisenburger; J O Armitage; W G Sanger
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

2.  Progress in mantle-cell lymphoma.

Authors:  Peter Martin; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

3.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis.

Authors:  Jeong A Han; Jong-Il Kim; Pat P Ongusaha; Daniel H Hwang; Leslie R Ballou; Alka Mahale; Stuart A Aaronson; Sam W Lee
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

Review 6.  Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.

Authors:  Julie M Vose
Journal:  Am J Hematol       Date:  2012-06       Impact factor: 10.047

7.  Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.

Authors:  L Lau; L M Hansford; L S Cheng; M Hang; S Baruchel; D R Kaplan; M S Irwin
Journal:  Oncogene       Date:  2006-09-18       Impact factor: 9.867

Review 8.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

9.  Role for the p53 homologue p73 in E2F-1-induced apoptosis.

Authors:  M Irwin; M C Marin; A C Phillips; R S Seelan; D I Smith; W Liu; E R Flores; K Y Tsai; T Jacks; K H Vousden; W G Kaelin
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

10.  Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Authors:  Devin G Roller; Mark Axelrod; Brian J Capaldo; Karin Jensen; Aaron Mackey; Michael J Weber; Daniel Gioeli
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.